Anika Therapeutics Affirms FY2026 Sales Guidance of $114.000M-$122.500M vs $117.220M Est

Benzinga Newsdesk www.benzinga.com Negative 75.3%

Neg 75.3% Neu 0% Pos 0%

Anika Therapeutics (NASDAQ:ANIK) affirms FY2026 sales outlook from $114.000 million-$122.500 million to $114.000 million-$122.500 million vs $117.220 million estimate.